Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin, Cyclosporine, Methylprednisone, and G-CSF in AA or MDS
NCT00806598Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2005
- Primary completion
- Jun 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin in aplastic anemia and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response up to 3 years. Started May 2005; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
aplastic anemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00806598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00806598.